- NewsCategory：
- All Company news Industry news
common105One result
-
1226
Bank of England Enhances Scrutiny of Lloyd’s Whistleblower Systems
The Bank of England has stepped up its monitoring of Lloyd’s of London’s whistleblowing systems, the central bank said on Monday, after reports this year about sexual harassment and bullying at the 330-year old insurance market.The Prudential Regulation Authority (PRA) said the insurance market had agreed to extra checks after informing the regulator its processes had been ineffective.he PRA said it was first made aware of issues at Lloyd’s in February when the market told the regulator its only anonymous whistleblowing channel for staff had not been operational since October 2017.Other whistleblowing channels were available while the anonymous hotline was down, the PRA said.Lloyd’s also failed to provide an annual whistleblowing report as expected, the regulator added.Lloyd’s has voluntarily agreed to additional requirements, including enhanced reporting of whistleblowing cases and training requirements for senior staff, the PRA said.Following press reports of widespread misconduct at Lloyd’s, the market published results of a survey in September that found nearly one in 12 employees working in the market had witnessed sexual harassment there in the past year, while a quarter had witnessed excessive drinking.Lloyd’s has tried to improve standards of behavior in the market this year, including introducing life bans from its building and a bullying and harassment hotline.The Lloyd’s market employs nearly 50,000 people and has 99 syndicate members offering insurance in specialist areas from ships to sculptures.“We are extremely disappointed by this failure in our internal controls, which serves to remind us all about the need for constant vigilance when it comes to these essential services,” a Lloyd’s spokesman said.“Lloyd’s employees can feel confident that we now have all the right mechanisms in place for them to report any wrongdoing, and that these systems are regularly monitored.”(Reporting by Iain Withers; editing by Louise Heavens and Edmund Blair)From:insurance journalOrganizer：China Insurance Digital & AI Development 2020Web:http://en.zenseegroup.com/p/560573/Contact:Ann 021-65650305 -
0822
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced today an exclusive agreement to in-license a triple reuptake inhibitor (TRI), TNX-1600 (formerly D-578), to treat posttraumatic stress disorder (PTSD) and potentially other central nervous system (CNS) disorders. The compound was developed and pharmacologically characterized by Aloke Dutta, Ph.D., professor of Pharmaceutical Sciences at Wayne State University, with funding from a National Institutes of Health grant (grant number MH084888), and the patents covering the compounds were licensed to TRImaran Pharma, Inc. (TRImaran). The transaction announced today is a license agreement with Wayne State and an asset acquisition with TRImaran.“We are excited to expand our pipeline and are looking forward to developing TNX-1600 as a potential treatment for PTSD,” said Seth Lederman, M.D., Tonix's President and Chief Executive Officer. “We plan to utilize our clinical experience in PTSD to evaluate the therapeutic benefit of TNX-1600. PTSD is a heterogeneous condition, so we believe different PTSD patients may respond to different medicines. In some cases, more than one drug will be required for effective treatment. TNX-1600 is our third drug candidate in development for PTSD. Our most advanced candidate is TNX-102 SL, which is in Phase 3 development. We are also developing TNX-601 which is entering a Phase 1 trial imminently. TNX-1600 is in the pre-IND phase of development with encouraging data from animal models of PTSD.”Frank Bymaster, Chief Scientific Officer and co-founder of TRImaran Pharma Inc. said, “TNX-1600 is a novel TRI that inhibits simultaneously the reuptake of three key neurotransmitters: serotonin, norepinephrine and dopamine. Each of these three neurotransmitters plays a key modulatory role in many CNS processes. Inhibiting reuptake of all three may provide an effective treatment for PTSD.”According to Dr. Aloke Dutta, “We have developed an innovative triple reuptake inhibitor, D-578, based on a unique pyran molecular scaffold to address the current therapeutic needs for PTSD and other neurological disorders. Based on our preliminary data, we expect a pharmacological synergy from their potent modulatory effect on the level of monoamine neurotransmitters in the brain which should facilitate effective treatment of these disorders.”Under the terms of the agreement, Tonix has been granted an exclusive license from Wayne State University for technology and patents related to TNX-1600 and other pyran-based compounds. Another member of the class, D-473, has also shown effects in a rodent model of depression.the 2019 Asia-pacific Pharmaceutical IP Leader Summit will be held in Beijing on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend. 2019 Asia-pacific Pharmaceutical IP Leader Summit Official registration and consultation channels:Contact：AnnPhone: 021-65650305Email：Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934/ -
1225
Health Provider in Arizona to Pay $6M Settlement in Breach
A Phoenix, Ariz.-based health provider has agreed to settle a lawsuit over a computer data breach that may have compromised health and personal data of about 3 million patients, employees, health insurance customers and others.The class action lawsuit against Banner Health stemmed from a 2016 cyberattack that exposed the information, The Arizona Republic reports.The settlement, up to $6 million, includes free insurance coverage for claims of up to $1 million to cover financial losses and two years of free credit monitoring through Identity Guard Total, officials said.When the breach occurred, Banner Health initially gave those affected a year of free credit monitoring, officials said.Those affected would be able to file claims for up to $500 for ordinary expenses or up to $10,000 for extraordinary expense reimbursement such as lost time at work or professional help with identity theft issues under the settlement agreement, company officials said.“All things considered, this settlement compares very favorably with those that have been approved in other data breach cases,” said Andrew Friedman, one of the lawyers representing the plaintiffs.The settlement was granted preliminary approval and is subject to final court approval April 21, officials said.“This is still a pending legal matter, so we are unable to discuss details. However, we are hopeful that it will be resolved soon, at which time those who were impacted can learn additional information,” provider spokeswoman Becky Armendariz said.Banner Health has also agreed to improve its information security systems, officials said.“In the meantime, data security is one of our highest priorities and we continue to work diligently to protect the sensitive information of our patients and employees,” officials said.From:insurance journalOrganizer：China Insurance Digital & AI Development 2020Web:http://en.zenseegroup.com/p/560573/Contact:Ann 021-65650305 -
0821
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communication with the FDA, in addition to a rolling submission of the marketing application. Moderna previously received Fast Track designation for its methylmalonic acidemia (MMA) program (mRNA-3704), which is now recruiting patients for a Phase 1/2 clinical study.“Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need. Fast Track designation supports our belief in the clinical potential of mRNA-1893 and the importance of developing an effective vaccine that can be rapidly developed and deployed,” said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna. “Our Zika program is part of Moderna’s broader commitment to improving global public health through developing mRNA vaccines to prevent the spread of infectious diseases.”mRNA-1893 contains an mRNA sequence encoding for the structural proteins of Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. Preclinical data published in The Journal of Infectious Diseases have shown that vaccination with mRNA-1893 protected against transmission of Zika virus during pregnancy in mice.1 mRNA-1893 is currently in a Phase 1 study evaluating safety, pharmacokinetics and pharmacodynamics in healthy volunteers.This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services (HHS); Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201600029C.from--Pharma Focus AsiaIn recent years, the size of the global pharmaceutical market has maintained a steady growth, with China, South Korea, India and other emerging markets presenting a rapid growth momentum. Due to the different intellectual property policies of different countries, the strategic layout of global intellectual property, the differences of pharmaceutical intellectual property policies of Asia-pacific countries, the patent review process, litigation procedures and Generic drug patent strategy have gradually become the hot spots of the pharmaceutical intellectual property industry. In this context, the 2019 Asia-pacific Pharmaceutical IP Leader Summit will be held in Beijing on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.2019 Asia-pacific pharma IP Leader Summit Official registration and consultation channels:Contact：AnnPhone: 021-65650305Email：Marketing@zenseegroup.com -
1224
AXA XL, Slice Labs, Microsoft to Offer Cyber Risk Management Tools
From:insurance journalAXA XL, the p&c and Specialty Risk Division of global insurer AXA, Slice Labs Inc. (Slice), an on-demand insurer of cloud technology, and Microsoft will work together to help improve cyber health and mitigate risks for Microsoft 365 Business, Office 365 Business Premium and Office 365 Business customers. The new relationship will give qualifying customers discounted access to Slice on-demand, cloud-based cyber insurance provided by AXA XL.Microsoft customers will have access to an end-to-end product that will help them secure their environment and give them the critical services and support for incident response and remediation in the event of a successful cyber-attack. These services are all part of AXA XL’s cyber insurance policy, which will be offered at discounted pricing to qualified customers who represent a lower insurance risk based on a security posture assessment that will be provided by Microsoft Secure Score.Recent Forrester survey results found that cybersecurity attacks are a business reality for small and mid-size businesses (SMBs), with nearly half having had a breach within the last year. What was more concerning was that 27% of SMBs were unaware if they’ve had a breach. One primary issue is that 58% of the SMBs struggle to maintain basic cybersecurity hygiene.“This new level of integration with Microsoft and Slice Labs reinforces the fact that insurance is no longer an after the fact product that companies should use as a band-aid when an incident occurs,” said John Coletti, Chief Underwriting Officer, AXA XL’s cyber insurance team in North America.Small business Microsoft customers can access AXA XL Cyber Insurance offered by Slice here.Slice Labs is the insurance engine behind tomorrow’s cloud-based, on-demand digital services ecosystems for the new economy. Through Slice’s Insurance Cloud Services (ICS) platform, Slice is enabling insurers, technology companies, and other service providers to build pay-as-you-go digital insurance products protecting the insured anytime and anywhere. Slice is licensed in the US and the UK.Organizer：China Insurance Digital & AI Development 2020Web:http://en.zenseegroup.com/p/560573/Contact:Ann 021-65650305
Contact Us
Zensee_Daystar online
© 2011-2016